NAVER D2SF Invests in AI-Driven Precision Medicine Company ImpriMed
<p>ImpriMed combines ex vivo functional testing with multimodal AI to support personalized cancer treatment decisions and drug development The investment is part of ImpriMed's $10 million Series A2 bridge round as the company advances U.S. commercialization and expands into Asia NAVER D2SF...</p>
Read original article ↗
Related Articles
Coupang turns to Taiwan as key hub for global growth
Taiwan has emerged as a key strategic hub for Coupang’s global growth, as the company brings fast delivery to more regio
SHENZHEN, Cina, 18 settembre 2026 /PRNewswire/ -- La Green Energy Development Conference & International Digital Energy
China's DRAM champion CXMT is reportedly planning to enter 3D NAND production as it plots 3D NAND research programs and
Security researchers used Claude to help them hack into OpenAI
A team of three independent security researchers at Hacktron says it took less than 72 hours for them to hack into OpenA